Clinical Trials Logo

Clinical Trial Summary

This is a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study to compare fixed dose combinations of AD109 and AD504 to atomoxetine or placebo in Obstructive Sleep Apnea.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05071612
Study type Interventional
Source Apnimed
Contact Ron Farkas, MD
Phone 617-500-8880
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date December 15, 2021
Completion date July 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04076332 - How "Shared Decision Making Decision-aid" Help Patients With Obstructive Sleep Apnea to Choose Treatment Plan N/A